Hexagon Bio’s mission to identify medicines encoded in the global metagenome, and bring them to patients.
While nature’s molecules have proven to be a rich source of potent medicines, their translation has been laborious and hindered by the lack of mechanistic understanding of the intended target. Hexagon Bio’s interdisciplinary platform uses data science, genomics, synthetic biology and automation to discover evolutionarily refined molecules and their protein targets directly from fungal genomes.
The TICker algorithm can identify human targets of cryptic natural products, prioritizing among thousands of candidates.
The HEx platform for production of Targeted Bioengineered Small Molecules (TBSMs) creates new chemical entities based on novel chemical scaffolds.
Fungi are similar to humans, sharing 6000 genes, many of which are potential therapeutic targets. Fungi have evolved medicines for human proteins over billions of years. And while over 5 million fungi exist on Earth, only a few thousand species have been studied to date.
Colin J. B. Harvey, Mancheng Tang, Ulrich Schlecht, Joe Horecka, Curt R. Fischer, Hsiao-Ching Lin, Jian Li, Brian Naughton, James Cherry, Molly Miranda, Yong Fuga Li, Angela M. Chu, James R. Hennessy, Gergana A. Vandova, Diane Inglis, Raeka S. Aiyar, Lars M. Steinmetz, Ronald W. Davis, Marnix H. Medema, Elizabeth Sattely, Chaitan Khosla, Robert P. St. Onge, Yi Tang, and Maureen E. Hillenmeyer.
We have ongoing collaborations with academic, governmental and industrial entities for genome sequencing projects.
Do you have fungal strains that you would like to have sequenced? We are looking to work with you! If you are interested in partnering with us, please get in touch.